Table 1

Patient Characteristics

Study Name/First Author (Ref. #)Publication YearnAge (yrs)Female (%)DM (%)Prior MI (%)Stented (%)
3T/2R (21)200926368/6826/2824/2848/3892/94
OPTIMIZE-IT (22)20094666/6527/29100/10017/18100/100
CLEAR PLATELETS-2 (23)200920065/6434/4134/3932/26100/100
De Luca et al. (24)200813263/6341/35100/10011/14100/100
Cuisset et al. (25)200814966/6425/2335/40NR100/100
ASIAD (26)200525462/6125/28100/10040/4299/100
Prati et al. (27)200514062/6217/1721/11NR98/98
Kurowski et al. (28)20055069/6716/1624/1672/72100/100
De Luca et al. (29)200512261/6430/40100/10013/11100/100
CLEAR PLATELETS (30)200512061/6233/4738/4227/2893/93
Claeys et al. (31)200520069/6531/3017/1615/2399/97
ISAR-SWEET (11)200470168/6727/24100/10035/3390/90
ISAR-SMART-2 (32)200450267/6627/2726/3038/3668/69
Okmen et al. (33)200411954/5818/148/1033/2684/87
DANTE (34)20049659/6147/55100/10067/33100/100
ISAR-REACT (10)20042,15965/6623/2421/2032/3391/90
Juergens et al. (35)200289459/5917/1717/1346/4698/98
Tamburino et al. (36)200210761/6313/1228/2765/69100/100
TOPSTAR (37)20029664/6626/2420/2642/3592/91
ESPRIT (38)20012,06462/6227/2820/2132/3195/97
Galassi et al. (39)199910661/6313/1228/2765/69100/100
EPISTENT (40)19981,60359/5925/2620/2150/5597/96

All data are formatted as treatment/control and are reported as mean value unless noted otherwise.

ASIAD = Abciximab in Stenting Inhibits restenosis Among Diabetics; CLEAR PLATELETS = Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets; DANTE = Diabetes Abciximab SteNT Evaluation; DM = diabetes mellitus; EPISTENT = Evaluation of Platelet IIb/IIIa Inhibitor for Stenting; ESPRIT = Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy; ISAR-REACT = Intracoronary Stenting and Antithrombotic Regimen–Rapid Early Action for Coronary Treatment; ISAR-SMART = Intracoronary Stenting or Angioplasty for Restenosis in SMall ARTeries; ISAR-SWEET = Intracoronary Stenting and Antithrombotic Regimen: is abciximab a Superior Way to Eliminate Elevated Thrombotic risk in diabetics; MI = myocardial infarction; NR = not reported; OPTIMIZE-IT = OPtimal TIrofiban bolus to reduce post-PCI Myonecrosis and Improve coronary flow randomized Evalution In diabeTics; TOPSTAR = Troponin in planned PTCA/stent implantation with or without administration of the glycoprotein IIb/IIIa Receptor Antagonist Tirofiban.

  • Patients were selected for being poor responders to clopidogrel or aspirin.

  • Median age.

  • Defined as recent MI.